Italy

Population 2018: 61 million

<table>
<thead>
<tr>
<th>Estimates of TB burden*, 2018</th>
<th>Number (thousands)</th>
<th>Rate (per 100 000 population)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total TB incidence</td>
<td>4.3 (3.7–4.9)</td>
<td>7 (6–8.1)</td>
</tr>
<tr>
<td>HIV-positive TB incidence</td>
<td>0.2 (0.11–0.32)</td>
<td>0.34 (0.19–0.53)</td>
</tr>
<tr>
<td>MDR/RR-TB incidence</td>
<td>0.17 (0.11–0.25)</td>
<td>0.28 (0.18–0.41)</td>
</tr>
<tr>
<td>HIV-negative TB incidence</td>
<td>0.34 (0.34–0.34)</td>
<td>0.56 (0.55–0.57)</td>
</tr>
<tr>
<td>HIV-positive TB mortality</td>
<td>0.031 (0.015–0.054)</td>
<td>0.05 (0.02–0.09)</td>
</tr>
</tbody>
</table>

Estimated proportion of TB cases with MDR/RR-TB, 2018
- New cases: 2.8% (1.8–4.3)
- Previously treated cases: 13% (7.7–21)

TB case notifications, 2018
- Total new and relapse: 3,777
  - % tested with rapid diagnostics at time of diagnosis: 0%
  - % with known HIV status: 71%
  - % pulmonary: 80%
  - % children aged 0–14 years: 4%
  - % women: 31%
  - % men: 65%
- Total cases notified: 3,912

Universal health coverage and social protection
- TB treatment coverage (notified/estimated incidence), 2018: 88% (77–100)
- TB patients facing catastrophic total costs: 9% (7–10)
- TB/HIV care in new and relapse TB patients, 2018: Number (%)
  - Patients with known HIV status who are HIV-positive on antiretroviral therapy
    - % of bacteriologically confirmed TB cases tested for rifampicin resistance**: 104%
      - New cases: 104%
      - Previously treated cases: 79%
    - Laboratory-confirmed cases**: MDR/RR-TB: 62, XDR-TB: 6
    - Patients started on treatment**: MDR/RR-TB: , XDR-TB: 47

Drug-resistant TB care, 2018
- % of bacteriologically confirmed TB cases tested for rifampicin resistance**: 104%
  - New cases: 104%
  - Previously treated cases: 79%
- Laboratory-confirmed cases**: MDR/RR-TB: 62, XDR-TB: 6
- Patients started on treatment**: MDR/RR-TB: , XDR-TB: 47

Treatment success rate and cohort size
- New cases registered in 2017
  - Success: 90%
  - Cohort: 83%
- Previously treated cases registered in 2017
  - Success: 91%
  - Cohort: 83%
- MDR/RR-TB cases started on second-line treatment in 2016
  - Success: 90%
  - Cohort: 80%
- XDR-TB cases started on second-line treatment in 2016
  - Success: 90%
  - Cohort: 80%

TB preventive treatment, 2018
- % of HIV-positive people (newly enrolled in care) on preventive treatment
- % of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment

TB financing, 2019
- National TB budget (US$ millions)

* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Calculated for pulmonary cases only
* Includes cases with unknown previous TB treatment history
** Includes patients diagnosed before 2018 and patients who were not laboratory-confirmed

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
Generated: 2020-04-11
Data: www.who.int/tb/data